PTPRC and acute myeloid leukemia: Strikingly, in two independent PDX models of AML (AML 01-254-2014 and AML01-173-2015), S55746/S63845 led to cytoreduction of AML after only 5 days of treatment as assessed by immunohistological staining of mouse sternums (Fig. 5a, b) or flow cytometric enumeration of human CD45 + blasts from flushed femurs (Fig. 5c, d).